Alexza Pharmaceuticals Announces Intent to Reacquire U.S. Rights for ADASUVE® (loxapine) inhalation powder (PR Newswire)

MOUNTAIN VIEW, Calif., Oct. 30, 2015 /PRNewswire/ — Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it plans to reacquire the U.S. rights for ADASUVE ® (loxapine) inhalation powder from Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., with an estimated target completion date of January 1, 2016. Alexza and Teva also plan…